PAOLA-1 (2023 Update): Final Overall Survival Results — Olaparib plus Bevacizumab First-Line Maintenance in Ovarian Cancer Last updated on Jun 8, 2026 Previous GYOEDU Resident: BRCA, Genetics and Parp Inhibitors Next Publications Update # 79
